Todorova, Margarita G.
Scholl, Hendrik P. N.
della Volpe Waizel, Maria
Funding for this research was provided by:
SAMW (YTCR 11/17)
Article History
Received: 5 May 2020
Revised: 15 July 2020
Accepted: 25 August 2020
First Online: 10 September 2020
Change Date: 24 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00417-020-04975-3
Compliance with ethical standards
: This study was approved by the local IRB (Ethics Commission of Central and Northern Switzerland, EKNZ Basel Switzerland; trial number EKNZ BASEC 2017-00937).
: The sponsor had no role in the design or conduct of this research.
: Margarita G. Todorova was partially supported by unrestricted grant from OPOS (Stiftung Ostschweizerische Pleoptik- and Orthoptik-Schule). Dr. Maria della Volpe Waizel was generously supported by the SAMW (Schweizerische Akademie der Medizinischen Wissenschaften), the Bangerter Foundation, and the SNF (Swiss National Science Foundation) with ad personam grants. Dr. Hendrik Scholl is supported by the Swiss National Science Foundation, National Center of Competence in Research Molecular Systems Engineering “Molecular Systems Engineering,” the Wellcome Trust, and the Foundation Fighting Blindness Clinical Research Institute.Dr. Scholl is a member of the Scientific Advisory Board of: Astellas Institute for Regenerative Medicine; Gensight Biologics; Ionis Pharmaceuticals, Inc.; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd.; Novartis Pharma AG (CORE); and Retinagenix LLC. Dr. Scholl is paid consultant of: Boehringer Ingelheim Pharma GmbH & Co; Gerson Lehrman Group; and Guidepoint.Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of ReNeuron Group Plc/Ora Inc. and member of the Steering Committee of Novo Nordisk (FOCUS trial).Dr. Scholl is co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a non-profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Johns Hopkins University and Bayer Pharma AG have an active research collaboration and option agreement. These arrangements have also been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) in accordance with its conflict of interest policies.Dr. Hendrik Scholl is principal investigator of grants at the USB sponsored by the following entities: IVERIC bio (Ophthotech Corporation), Kinarus AG, and Novartis Pharma AG. Grants at USB are negotiated and administered by the institution (USB) which receives them on its proper accounts. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.